I recently had the pleasure of experiencing Delta and Comair‘s friendly customer support as I attempted to make the 90 minute trip from Minneapolis to Toronto on DL 6350.
A series of mechanical failures on Delta/Comair‘s aircraft resulted in me arriving at my destination seventeen hours late. After the first flight was canceled due to mechanical problems, I had the pleasure of waiting in line for two hours to be booked into the local Radisson (an excellent hotel) by the friendly Delta team members. The generous $6 vouchers for dinner and breakfast supplied me with an excellent opportunity to experiment with caloric restriction. The next morning, as I awaited takeoff on my rebooked flight, I had ample opportunity to sleep unperturbed by turbulence as we sat on the ground waiting for the pilot ultimately scrub the flight due to the second mechanical malfunction of my trip. I had ample opportunity to contemplate the odds of two mechanical problems in a row and the implications for the safety of Delta/Comair‘s aircraft as the polite crew kept assuring us that a replacement aircraft would be available, in sequential twenty-minute increments. They were also very prompt to offer us travel vouchers after some distressed passengers loudly voiced their frustration over the extensive delay and uncertain nature of our egress. When we finally boarded a functional aircraft and were airborne, the Comair stewardess was kind enough to offer free premium beverages (valued at $5-$7), which surprisingly satiated the more vocal complainers.
It took me nearly twenty hours to complete a ninety minute flight. While I would have preferred it if Delta/Comair had rebooked me on another flight, or preferably, a more reliable airline, I did appreciate the opportunity to experience their friendly yet ineffective customer support and confidence-shaking maintenance regime. I look forward to selling my travel voucher on Ebay and finding a more reliable airline.
I received the following response when I submitted a formal complaint to Delta:
Thank you for contacting us. On behalf of everyone at Delta Air Lines, I appreciate the opportunity to be of assistance with your request. I am truly sorry for that we are unable to go through your concern. We recently experienced some technical problems with our online form and it appears we may not have received a portion of the information you provided. In order to fully review your concerns, we ask that you resend your message.
So I guess that brings the number of technical problems to three!
Many biotechnology entrepreneurs favorably look back at times when financing and regulatory approval were easier to obtain. While future periods of investor exuberance may return, it is better to see these as market aberrations.
In periods of investor exuberance companies have been pushed to focus on low-probability, high-return, objectives such as approval and successful marketing of novel drugs for large markets. When this strategy works it is very profitable, but the more likely outcome is failure and destruction of wealth. A favorable strategy is to build a slower, stronger, company than can withstand developmental setbacks.
In a recent issue of the Journal of Commercial Biotechnology I expanded on this concept, providing examples from computer software and bioinformatics where initial products were outside of the company’s target market. This strategy can differentiate a company from competitors, provide evidence of ability to successfully execute on plans, and even provide revenues. For more, see the freely-available editorial on the JCB’s website.
Do you agree? Disagree? Sound-off in the comments below.
The public portion of the International Symposium Development of an R&D Cluster in Okinawa has been posted. The symposium brought experts from around the world, with a particular emphasis on regions such as San Diego, Singapore, and Israel. Complete coverage, including video links in English and Japanese are on the Okinawa Institute for Science and Technology website.
I will be writing up my comments in a future issue of the Journal of Commercial Biotechnology, and linking to them from this blog.
This is a guest post from BiotechBlog reader Jack Lundee
Technology Continues to Fight Aids
In 2008, Sub-Saharan Africa was populated with over 22 million HIV+ inhabitants, and currently there are over 5 million Southern Africans infected with the virus. Worldwide, there are upwards of 40 million people infected with HIV, a very frightening number. But with the coming of the 22nd annual World AIDS Day, it’s important to take note the progress that has been made in the fight against HIV/AIDS. At the same time, it’s very vital we familiarize ourselves with a couple great HIV research and technology investors.
Granted, there have already been major advances concerning affordable microbicides and vaccines as preventative measures against the virus. Similarly, the introduction of low-cost antiretroviral drugs has allowed people already infected to lead longer, healthier and happy lives.
This can most certainly be attributed to tremendous associations like the CGI (Clinton Global Initiative). The Clinton Global Initiative has put a tremendous amount of money into AIDS research. Known for his work in raising money for Hurricane/Tsnuami victims, former President Clinton and his close personal aide Doug Band also have great interest in tackling one of the deadliest STDs in the world, HIV/AIDS. Back in 2006, Clinton helped open people’s eyes to the severity of the disease in foreign states by traveling deep into Burma with the crew of 60 Minutes.
Before this however, he introduced CHAI (Clinton Health Access Initiative), outlined specifically as “a global health organization committed to strengthening integrated health systems in the developing world and expanding access to care and treatment for HIV/AIDS, malaria and tuberculosis.” Their main objective was to travel to these third world countries like Burma, and distribute various treatments, which weren’t currently available to sufferers. Since it’s beginning, the organization has helped more than 2 million people gain access to medicines needed for treatment. But the efforts of Former President Clinton and his close personal aide did not end there. The CGI continues to receive funding for HIV related projects in third world countries like Southern Africa.
In their latest endeavor, they’ve joined forces with HP (Hewlett Packard) to deliver technologies that will capture, manage and return early diagnosis for infants. This translates to indentifying the virus in an infant within one to two days, which is a huge improvement from previous paper based systems. How is this important? Newly borne are especially susceptible to the disease as their carriers can very easily transmit. Similarly, it’s very crucial that they begin treatment as soon as possible to ensure survival; without, they are typically unable to survive past age two. In a statement to the press, Clinton stated, “I’m pleased HP’s technology and expertise will enable the partnership with CHAI to save the lives of more than 100,000 infants in Kenya each year, and in the process, demonstrate how the private sector can and should operate in the developing world.”
Within their first year, HP is expected to return results concerning HIV testing for nearly 70,000 infants in Kenya. The technologies introduced will also allow for real-time medical data, which will be viewable to health professionals across Kenya.
Known for it’s incredibly high number of HIV+ citizens, Africa remains one of the greatest challenges for organizations like CHAI/CGI today. Recent advancements in technology combined with the help of Doug Band and Former President Clinton have helped lessen casualty rates and permitted people to live more productive lives. And although a cure remains unfound, HP and the CGI have provided great technological steps in the right direction towards eliminating the virus for good.
Jack Lundee is a writer for Everythingleft.wordpress.com and Shadesofgreen.info. With a graduates from the Newhouse School of Communications, he’s an avid supporter of all things left and progressive.
Drug Patent Expirations in December 2010
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number|| Patent Expiration|
|CHILDREN’S MOTRIN||Mcneil Cons||ibuprofen||5,215,755*PED||Dec 1, 2010|
|JUNIOR STRENGTH MOTRIN||Mcneil Cons||ibuprofen||5,215,755*PED||Dec 1, 2010|
|MOTRIN||Mcneil Ped||ibuprofen||5,215,755*PED||Dec 1, 2010|
|ZYFLO CR||Cornerstone Therap||zileuton||4,873,259||Dec 9, 2010|
|ZYFLO||Cornerstone Therap||zileuton||4,873,259||Dec 10, 2010|
|ANDRODERM||Watson Labs||testosterone||5,164,190||Dec 11, 2010|
|ANDRODERM||Watson Labs||testosterone||5,152,997||Dec 11, 2010|
|OXYTROL||Watson Labs (utah)||oxybutynin||5,164,190||Dec 11, 2010|
|ALORA||Watson Labs||estradiol||5,164,190||Dec 11, 2010|
|ZANTAC 150||Boehringer Ingelheim||ranitidine hydrochloride||5,098,715||Dec 20, 2010|
|QUIXIN||Santen||levofloxacin||5,053,407||Dec 20, 2010|
|IQUIX||Santen||levofloxacin||5,053,407||Dec 20, 2010|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com